# Randomized Controlled Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients.

> **NCT02050529** · PHASE2 · COMPLETED · sponsor: **Dow University of Health Sciences** · enrollment: 190 (actual)

## Conditions studied

- Hypertension, Pregnancy Induced
- Hydralazine Adverse Reaction
- Pre-eclampsia
- Pre-eclampsia Superimposed Pre-existing Hypertension

## Interventions

- **DRUG:** Labetalol
- **DRUG:** Hydralazine

## Key facts

- **NCT ID:** NCT02050529
- **Lead sponsor:** Dow University of Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2014-09
- **Final completion:** 2015-03
- **Target enrollment:** 190 (ACTUAL)
- **Last updated:** 2018-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02050529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02050529, "Randomized Controlled Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02050529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*